Sector |
|
Compare with Sector peers |
Industry |
|
Compare with Industry peers |
Website | http://www.biogenpharma.shop | |
Market Cap | 54.17 Cr. | |
Enterprise Value(EV) | 59.01 Cr. | 2023-09 |
Financial Indicators | ||
---|---|---|
Earnings per share (EPS) | 0.02 | Trailing Twelve Months Ending 2023-09 |
Price-Earning Ratio (PE) | 44.00 | Trailing Twelve Months Ending 2023-09 |
Industry PE | 47.29 | Trailing Twelve Months Ending 2023-09 |
Book Value / Share | 0.85 | Trailing Twelve Months Ending 2023-09 |
Price to Book Value | 0.97 | Calculated using Price: 0.83 |
Dividend Yield | 0.00 | Period Ending 2023-03 |
No. of Shares Subscribed | 65.26 Cr. | 652,603,000 Shares |
FaceValue | 1 | |
About Biogen Pharmachem Industries Ltd. | ||
Sun Techno Overseas Ltd., formerly Wellworth Overseas Limited, is an India-based company.In 2011 the company changed its name from Wellworth Overseas Ltd. to Sun Techno Overseas Ltd. |
1 Day |
|
+2.44% |
1 Week |
|
+5.00% |
1 Month |
|
+12.00% |
3 Month |
|
+9.09% |
6 Month |
|
+31.25% |
1 Year |
|
-1.18% |
2 Year |
|
+52.73% |
5 Year |
|
+342.11% |
10 Year |
|
+281.82% |
9 years | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
Return on Equity (%) | -0.22 | -0.05 | -0.20 | -11.40 | -0.01 | -0.21 | -2.92 | -0.02 | 0.84 | |
Return on Capital Employed (%) | -0.14 | -0.04 | -0.19 | -11.33 | -0.01 | -0.21 | -2.91 | -0.02 | 0.84 | |
Return on Assets (%) | -0.13 | -0.04 | -0.18 | -11.01 | -0.01 | -0.21 | -2.91 | -0.02 | 0.83 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
Shh. Funds | 61 | 61 | 61 | 54 | 54 | 56 | 54 | 54 | 55 | 56 | |
Non Curr. Liab. | 9 | 8 | 2 | 2 | 2 | 0 | 6 | ||||
Curr. Liab. | 3 | 0 | 0 | 0 | 1 | 0 | 0 | 1 | 0 | 0 | |
Minority Int. | |||||||||||
Equity & Liab. | 73 | 69 | 63 | 56 | 58 | 56 | 54 | 55 | 55 | 62 | |
Non Curr. Assets | 45 | 55 | 63 | 49 | 50 | 48 | 52 | 53 | 55 | 61 | |
Curr. Assets | 29 | 14 | 0 | 7 | 8 | 8 | 3 | 2 | 0 | 0 | |
Misc. Exp. not W/O | |||||||||||
Total Assets | 73 | 69 | 63 | 56 | 58 | 56 | 54 | 55 | 55 | 62 |
Particulars | 10 years | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09 Rs. Cr. TTM |
Net Sales | 1 | 2 | 2 | 1 | |||||||
Other Income | 0 | 0 | 1 | 1 | |||||||
Total Income | 0 | 1 | 2 | 2 | 1 | 2 | |||||
Total Expenditure | 0 | 0 | 0 | -7 | -1 | 0 | -3 | -2 | 0 | -1 | |
PBIDT | 0 | 0 | 0 | -7 | 0 | -2 | 0 | 0 | 1 | ||
Interest | |||||||||||
Depreciation | |||||||||||
Taxation | |||||||||||
Exceptional Items | |||||||||||
PAT | 0 | 0 | 0 | -7 | 0 | -2 | 0 | 0 | 1 | ||
Adjusted EPS | 0 | 0 | 0 | 0 |
Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
Cash Fr. Operatn. | 0 | -7 | 5 | 0 | -14 | 0 | -1 | 4 | 1 | 2 | |
Cash Fr. Inv. | -9 | 17 | 17 | 4 | 14 | -1 | 2 | -4 | -1 | -2 | |
Cash Fr. Finan. | 10 | -11 | -22 | -4 | -1 | 1 | 0 | 0 | |||
Net Change | 1 | -1 | 0 | 0 | 0 | 0 | 0 | 0 | |||
Cash & Cash Eqvt | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Wed, 01 Nov 2023
Un-Audited Financial Result Quarter And Half Year Ended On 30Th September 2023 Pursuant To Regulation 33 Of The SEBI (LODR) Regulations 2015. PFA |
Wed, 01 Nov 2023
Board Meeting Outcome for Un-Audited Financial Result Quarter And Half Year Ended On 30Th September 2023 Pursuant To Regulation 33 Of The SEBI (LODR) Regulations 2015. In compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 please find attached herewith Un-audited financial result for quarter and half year ended on 30th September 2023 and The meeting commenced at 04:30 P.M. and concluded at 05:00 P.M. Kindly take the same on your record and oblige. Thanking You |
Thu, 26 Oct 2023
Board Meeting Intimation for Compliance Of Regulation 29 Of SEBI (LODR) Regulations 2015 - Intimation Of Board Meeting. Biogen Pharmachem Industries Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 01/11/2023 inter alia to consider and approve Notice pursuant to regulation 29 of SEBI (LODR) Regulation 2015 be and is hereby given that the meeting of the Board of Directors of the Company will be held on Wednesday November 1 2023 inter alia to consider the Un-Audited financial results of the company for quarter and half year ended on September 30 2023 and also transact other business activities. Please take the above intimation in your records.Thanking you. |
Wed, 06 Dec 2023 |
|
|
|
|
|